Aclaris Therapeutics
ACRS
122 hedge funds and large institutions have $252M invested in Aclaris Therapeutics in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 34 increasing their positions, 40 reducing their positions, and 6 closing their positions.
317% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 6
55% more capital invested
Capital invested by funds: $163M → $252M (+$89.3M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
18% more funds holding
Funds holding: 103 → 122 (+19)
1.8% less ownership
Funds ownership: 79.09% → 77.29% (-1.8%)
15% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.81M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.23M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.87M |
| 4 |
State Street
Boston,
Massachusetts
|
+$994K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$926K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.82M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$3.11M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.42M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.27M |
| 5 |
Morgan Stanley
New York
|
-$1.67M |
ACRS Hedge Fund Activity: Q4 2025 in Review
122 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2025, worth a combined $252M — up 55% from $163M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ACRS positions and 6 closed out — a net gain of 19 holders — while 34 added to existing stakes and 40 trimmed.
The largest buyer was BlackRock, adding an estimated $2.81M. The largest seller was Adage Capital Partners, cutting an estimated $4.82M.
- 122 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2025, up from 103 in Q3 2025.
- Funds reported $252M of Aclaris Therapeutics stock for Q4 2025, up 55% quarter-over-quarter.
- 25 funds opened new Aclaris Therapeutics positions in Q4 2025 and 6 closed out, a net change of +19 holders.
- The largest Aclaris Therapeutics buyer in Q4 2025 was BlackRock, an estimated $2.81M added.
- The largest Aclaris Therapeutics seller in Q4 2025 was Adage Capital Partners, an estimated $4.82M sold.
Based on aggregated 13F filings for Q4 2025.